ReviewAnnals of clinical microbiology and antimicrobials2021
Bacteriophage therapy for inhibition of multi drug-resistant uropathogenic bacteria: a narrative review.
Review in Annals of clinical microbiology and antimicrobials, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed, 97 citations in OpenAlex.
- A Biological Approach to Antimicrobial Resistance in New and Old Bacterial Pathogens.Pathogens (Basel, Switzerland) · 2026Review
- Biofilm-Mediated Antimicrobial Resistance in PediatricAntibiotics (Basel, Switzerland) · 2026Review
- Whole-genome sequencing and integrative genomic data-driven profiling of Carbapenems-resistantData in brief · 2026Article
- A One Health Perspective onMicroorganisms · 2026Review
- Isolation, characterisation and potential applications of a novel bacteriophage targeting beta-lactam-resistant Staphylococcus saprophyticus.Scientific reports · 2026Article
- Non-specific Protein and Peptide Antibacterial Factors of Mammals.The protein journal · 2026Review
- Novel Koutsourovirus phages disrupt clinical multidrug-resistant Enterobacter cloacae biofilms: genomic and functional characterization.Folia microbiologica · 2026Article
- Bacteriophage Therapy AgainstMicroorganisms · 2026Review
- A novel synergistic action of phage vB_PaeP_GZMU_A1002 with allicin against carbapenem-resistant Pseudomonas aeruginosa.Biology direct · 2026Article
- A lytic bacteriophage vB_KpnP-6K2 inhibits ST11-KL64Frontiers in cellular and infection microbiology · 2026Article
- Phage and endolysin-based inhibition ofFrontiers in cellular and infection microbiology · 2026Review
- Current Insights into Antibiotic Resistance in UropathogenicAntibiotics (Basel, Switzerland) · 2025Review
- Characterization and genome analysis of the Klebsiella webervirus vB_KpnS_2146-302.Archives of virology · 2025Article
- Isolation and characterization of biofilm-disrupting proteus phage Premi.Scientific reports · 2025Article
- Characterization of a Phage-Encoded Depolymerase AgainstViruses · 2025Article
- Phage therapy for antimicrobial-resistant Klebsiella spp. infections: a review of mechanisms, synergies, and clinical potential.Archives of microbiology · 2025Review
- Isolation and characterization of a novel phage targeting Klebsiella pneumoniae K2 capsular type.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Phage-Antibiotic Synergy Enhances Biofilm Eradication and Survival in a Zebrafish Model ofInternational journal of molecular sciences · 2025Article
- Burden of multi-drug resistant bacterial isolates and its associated risk factors among UTI-confirmed geriatrics in Gondar town.Scientific reports · 2025Article
- Rapid formulation of a genetically diverse phage cocktail targeting uropathogenic Escherichia coli infections using the UTI89 model.Scientific reports · 2025Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multi-Drug Resistant (MDR) uropathogenic bacteria have increased in number in recent years and the development of new treatment options for the corresponding infections has become a major challenge in the field of medicine. In this respect, recent studies have proposed bacteriophage (phage) therapy as a potential alternative against MDR Urinary Tract Infections (UTI) because the resistance mechanism of phages differs from that of antibiotics and few side effects have been reported for them. Escherichia coli, Klebsiella pneumoniae, and Proteus mirabilis are the most common uropathogenic bacteria against which phage therapy has been used. Phages, in addition to lysing bacterial pathogens, can prevent the formation of biofilms. Besides, by inducing or producing polysaccharide depolymerase, phages can easily penetrate into deeper layers of the biofilm and degrade it. Notably, phage therapy has shown good results in inhibiting multiple-species biofilm and this may be an efficient weapon against catheter-associated UTI. However, the narrow range of hosts limits the use of phage therapy. Therefore, the use of phage cocktail and combination therapy can form a highly attractive strategy. However, despite the positive use of these treatments, various studies have reported phage-resistant strains, indicating that phage-host interactions are more complicated and need further research. Furthermore, these investigations are limited and further clinical trials are required to make this treatment widely available for human use. This review highlights phage therapy in the context of treating UTIs and the specific considerations for this application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.